News | Endovascular Aortic Repair | October 30, 2023

Philippe Généreux, MD Presents Novel Research on Aortic Stenosis from egnite, Inc.’s Database at TCT23

Key findings demonstrate patients with aortic stenosis have substantial untreated mortality risk across all levels of aortic stenosis severity, but aortic valve replacement rates remain low even for patients with severe aortic stenosis

Key findings demonstrate patients with aortic stenosis have substantial untreated mortality risk across all levels of aortic stenosis severity, but aortic valve replacement rates remain low even for patients with severe aortic stenosis

Getty Images


October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research on aortic stenosis (AS) was presented by cardiologist Philippe Généreux, MD, Director of the Structural Heart Program of Morristown’s Gagnon Cardiovascular Institute, at the Transcatheter Cardiovascular Therapeutics (TCT) conference. 

This study, simultaneously published in the Journal of the American College of Cardiology (JACC), leveraged egnite’s de-identified real-world database of over one million patients across 24 teaching and non-teaching United States health systems. Généreux and colleagues sought to unveil treatment patterns and outcomes associated with AS over 4 years. 

Key findings demonstrated: 

  • Patients with AS have substantial untreated mortality risk across all levels of AS severity, but rates of treatment with aortic valve replacement (AVR) remain low (even for patients with severe AS, ~60% were treated within 4 years) 
  • Moderate AS was almost as deadly as severe AS at 4 years without AVR 

“This research is the first of its kind to look at such a large cohort of AS patients over a four-year span. Findings serve as a stark reminder of the poor prognosis associated with untreated AS irrespective of severity, suggesting patients with moderate AS may benefit from intervention,” says Généreux. 

This study builds upon a robust body of medical research on the outcomes of patients with AS, highlighting the need for early identification and timely treatment of disease. 

For more information: www.egnitehealth.com 

Find more TCT23 conference coverage here 


Related Content

News | TCT

Oct. 11, 2024 – As the pace of change accelerates in healthcare, the most pressing questions in cardiovascular medicine ...

Home October 16, 2024
Home
News | TCT

November 9, 2023 — Medinbox, a global provider of video integrated collaboration systems for interventional rooms and ...

Home November 09, 2023
Home
News | TCT

October 30, 2023 — Shockwave Medical, Inc., which develops technologies for the treatment of cardiovascular disease, has ...

Home October 30, 2023
Home
News | TCT

October 26, 2023 — The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued ...

Home October 26, 2023
Home
News | TCT

October 26, 2023 — A new study presented at TCT 2023 revealed inequities in access to mechanical circulatory support in ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Elixir Medical, developer of novel cardiovascular technologies, announced positive six-month clinical ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Medtronic plc, a global leader in healthcare technology, announced four-year results from the Evolut ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Information on a new double lumen catheter was presented by Nabil Dib, MD, MSc, FACC, FESC, during ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — For its novel multi-lumen stent system for interventional adjustment of pulmonary blood flow in ...

Home October 25, 2023
Home
Feature | TCT | By Melinda Taschetta-Millane

Innovation. Connection. Inspiration. The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference, the ...

Home October 20, 2023
Home
Subscribe Now